注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉

智通财经09-21 16:54

【注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉】一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。NAION是一种罕见的眼部疾病，可能导致突发且永久性视力丧失。关于上述报道，记者联系了诺和诺德、礼来方面，截至发稿，未获正式回应。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669759159?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-21 16:54","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2669759159","market":"us","top_or_hot":-1,"title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉】</b>一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。NAION是一种罕见的眼部疾病，可能导致突发且永久性视力丧失。关于上述报道，记者联系了诺和诺德、礼来方面，截至发稿，未获正式回应。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉】</b>一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。NAION是一种罕见的眼部疾病，可能导致突发且永久性视力丧失。关于上述报道，记者联系了诺和诺德、礼来方面，截至发稿，未获正式回应。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOC","symbol_name":"Corgi NVO 2x Daily ETF","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2669759159","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669759159","pubTimestamp":1789980888,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉】一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVOC":"Corgi NVO 2x Daily ETF","NBDS":"Neuberger Disrupters ETF","FXH":"First Trust Health Care AlphaDEX Fund","XLVI":"The Health Care Select Sector SPDR Premium Income Fund","CURE":"Direxion Daily Healthcare Bull 3X ETF","RSPH":"Invesco S&P 500 Equal Weight Health Care ETF","TRUH":"VanEck Healthcare TruSector ETF","NVOX":"2倍做多NVO ETF-Defiance","PINK":"SIMPLIFY HEALTH CARE ETF","BGIA":"Baillie Gifford International Alpha ETF","NVOH":"Novo Nordisk A/S B Shares ADRhedged","MEDI":"HARBOR HEALTH CARE ETF","IYH":"iShares U.S. Healthcare ETF","PJP":"INVESCO PHARMACEUTICALS ETF","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","FHLC":"Fidelity MSCI Health Care Index"},"translate_title":"Could injecting celebrity weight loss pills cause blindness? Eli Lilly and Novo Nordisk, two giants, were sued by patients in the US.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLVI":1.5,"FHLC":1.5,"FXH":1.5,"NBDS":1.5,"NVOC":1.5,"THNR":1.5,"MEDI":1.5,"PINK":1.5,"CURE":1.5,"IYH":1.5,"RSPH":1.5,"TRUH":1.5,"NVOX":0.6,"PJP":1.5,"BGIA":1.5,"NVOH":0.6},"content_text":"【注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉】一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。NAION是一种罕见的眼部疾病，可能导致突发且永久性视力丧失。关于上述报道，记者联系了诺和诺德、礼来方面，截至发稿，未获正式回应。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669759159","isCrawlerRequest":true}